Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
02:26pm, Thursday, 16'th Jul 2026
ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?
11:46am, Wednesday, 15'th Jul 2026
AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company's post-Humira growth strategy. Despite Humira's U.S. patent expiry in 2023, AbbVie has successfully
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Wednesday, 15'th Jul 2026
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
07:45am, Wednesday, 15'th Jul 2026
Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-d
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
10:30am, Tuesday, 14'th Jul 2026
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?
09:04am, Tuesday, 14'th Jul 2026
VYM offers broader diversification with lower costs, while HDV is a more concentrated ETF with a heavy weightage on defensive stocks.
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
08:05am, Tuesday, 14'th Jul 2026
SkinMedica ® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb
05:00am, Tuesday, 14'th Jul 2026
Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
05:06pm, Monday, 13'th Jul 2026
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon
3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors
12:15pm, Monday, 13'th Jul 2026
You need to look beyond the tech sector to find great dividend stocks for the long term.
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
08:15pm, Saturday, 11'th Jul 2026
AbbVie has a portfolio of attractive drugs, including branded products that are off-patent but still highly profitable. The company's acquisition of Apogee helps expand its drug pipeline.
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
08:24pm, Friday, 10'th Jul 2026
On July 10, 2026, AbbVie Inc (ABBV) shares fell 0.7% to a current price of $248.08. This price is down from a 52-week high of $261.64 and remains significantly
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
11:30am, Friday, 10'th Jul 2026
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Thursday, 09'th Jul 2026
In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
10:01am, Thursday, 09'th Jul 2026
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
